http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
-
Cipla USA Strengthens Lung Leadership with Community Wellness Initiatives
-
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension
-
Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL
-
Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products
-
Cipla USA Earns 2023 Great Place To Work Certification™
-
Cipla EU to Invest EUR 15 million in Ethris, initiating a strategic collaboration
-
CIPLA ANNOUNCES LAUNCH OF LEUPROLIDE ACETATE INJECTION DEPOT (22.5Mg)
-
Cipla receives USFDA approval for generic version of Revlimid® (Lenalidomide capsules)
-
Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa
-
Cipla to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)
-
Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL)
-
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
-
Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand
-
Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)
-
Cipla to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Cipla Announces Settlement of REVLIMID® (lenalidomide) Capsules Patent Litigation
-
Cipla launches 'Covi-G' for COVID-19 rapid antibody detection
-
Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack)
-
Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)
-
Cipla Receives Final Approval for Generic Version of Shire's Firazyr® (Icatibant Injectable Pre-Filled Syringe 30mg/3mL)
-
Cipla Launches CIPREMI (remdesivir Lyophilised Powder for Injection 100 mg), the Only U.S. FDA Approved Emergency Use Authorisation (EUA) Treatment for Patients With Severe COVID-19 Disease
-
Cipla Receives Final Approval for Generic Version of Migranal® (Dihydroergotamine Mesylate Nasal Spray 4mg/mL) With a Competitive Generic Therapy Designation
-
Cipla Files ANDA for Generic Version of GSK's Advair Diskus®
-
Cipla Enters Into a Licensing Agreement With Gilead to Expand Access to COVID-19 Treatment
-
Cipla Receives Final Approval for Generic Version of Proventil® HFA Inhalation Aerosol (Albuterol Sulfate Inhalation Aerosol 90mcg (Base)/Actuation)
-
Cipla Receives Final Approval for Generic Version of AstraZeneca Pharmaceutical's Nexium® (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg)
-
Alvotech and Cipla Gulf Enter Into a Partnership for the Commercialization of Key Biosimilar in Select Emerging Markets
-
Cipla USA Furthers AMR Stewardship With Acquisition of Key Anti-infective ZEMDRI™ (IV Plazomicin)
-
InvaGen (a Cipla Subsidiary) Receives Final Approval for Generic Version of Pfizer's Lyrica® (Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg)
-
Pulmatrix (PULM), Cipla Technologies Enter Agreement for Development and Commercialization of Pulmazole
-
Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole™
-
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
-
Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar

